Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 7, 2022

Primary Completion Date

July 1, 2026

Study Completion Date

July 1, 2026

Conditions

Smoldering Plasma Cell Myeloma

Interventions

DRUG

Cholestyramine

Given PO

DRUG

Leflunomide

Given PO

Trial Locations (4)

RECRUITING

Memorial Sloan Kettering Cancer Center, New York

RECRUITING

Atrium Health University City/LCI-University, Charlotte

RECRUITING

Wayne State University/Karmanos Cancer Institute, Detroit

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER